A team of researchers have applied a novel blood test that can detect early signs of potentially fatal lung damage in cancer ...

ADCs, including the widely used cancer drug Enhertu (trastuzumab deruxtecan), represent a new wave of targeted therapies.

Fact checked by Marley Hall Medically reviewed by Marla Anderson, MD The Food and Drug Administration (FDA) granted priority review for Enhertu (fam-trastuzumab deruxtecan-nxki) in 2024. This drug ...

Baylor Medicine’s Interstitial Lung Disease (ILD) program offers specialized and multidisciplinary care. We bring together a unique team of physicians of multiple sub-specialties for patients with a ...

MoA International Fund earns a High Process Pillar rating. The largest contributor to the rating is its parent firm's impressive long-term risk-adjusted performance, as shown by the firm's average ...

MoA Aggressive Allocation Fund earns a High Process Pillar rating. The leading factor in the rating is its parent firm's excellent long-term risk-adjusted performance, as shown by the firm's ...

The Program for Pulmonary Fibrosis and Interstitial Lung Disease's mission is to provide state of the art evaluation and treatment for patients with interstitial lung diseases (ILD). The University of ...

Diffuse (interstitial) lung disease includes a wide variety of relatively uncommon conditions presenting with characteristic clusters of clinical features and marked by an immune response.

Additionally, the study did not establish the efficacy of T-Duo in patients previously treated with trastuzumab deruxtecan. This study was supported by Byondis B.V. Co-authors Evelyn van den Tweel ...

TOKYO & BASKING RIDGE, N.J.--(BUSINESS WIRE)--The first patients have been dosed in three global, randomized phase 3 trials evaluating the efficacy and safety of datopotamab deruxtecan (Dato-DXd ...

The Lung Institute provides comprehensive diagnostics and treatments to patients with illnesses that affect the lungs and breathing, including lung cancer, chronic obstructive pulmonary disease, ...

Tolebrutinib for treating relapsing multiple sclerosis TS ID 11845 Technology appraisal guidance Toripalimab with chemotherapy for treating advanced oesophageal squamous cell cancer without previous ...